Stryker Corporation $SYK Stake Reduced by Waverly Advisors LLC

Waverly Advisors LLC trimmed its stake in Stryker Corporation (NYSE:SYK) by 5.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 43,388 shares of the medical technology company’s stock after selling 2,440 shares during the quarter. Waverly Advisors LLC’s holdings in Stryker were worth $13,660,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. VanderPol Investments L.L.C. lifted its position in Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares during the last quarter. KCM Investment Advisors LLC increased its stake in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC increased its stake in shares of Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares during the period. Tcfg Wealth Management LLC raised its holdings in shares of Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares during the last quarter. Finally, ICW Investment Advisors LLC boosted its position in shares of Stryker by 0.6% during the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after buying an additional 30 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 8.9%

NYSE SYK opened at $276.16 on Wednesday. The company has a market capitalization of $105.93 billion, a P/E ratio of 28.62, a PEG ratio of 1.90 and a beta of 0.76. Stryker Corporation has a 12 month low of $275.10 and a 12 month high of $395.90. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company’s 50 day simple moving average is $327.52 and its 200 day simple moving average is $328.30.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.3%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SYK. Piper Sandler decreased their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. UBS Group began coverage on Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target for the company. Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. Finally, Raymond James Financial set a $370.00 price target on shares of Stryker in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Buying and Selling at Stryker

In other news, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.